Testing outcomes with EGFR pills for uncommon lung cancer mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have advanced non-small cell lung cancer confirmed by a tissue biopsy.
- Your cancer type is not squamous (it’s a non-squamous type).
- Your tumor has an uncommon EGFR mutation.
- You can safely take chemotherapy treatments (no known reasons you cannot).
- You are not currently pregnant and not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two combination maintenance drugs (a targeted pill and an anti-angiogenesis drug) for people whose non-small cell lung cancer has turned into small cell lung cancer after EGFR-targeted therapy. The goal is to see if this combination can help keep the cancer under control.
This study looks at how well a type of targeted therapy pill (called a third-generation EGFR-TKI) works when taken after surgery for early-stage non-small cell lung cancer that has certain high-risk features and an EGFR mutation. It aims to see if this treatment can help prevent the cancer from coming back.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
This trial tests an experimental pill called Sutetinib for people with advanced non-small cell lung cancer that has a rare EGFR gene change. It aims to see if the drug can shrink tumors and improve survival.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This trial compares two targeted therapy pills, aumolertinib and osimertinib, for people with a specific EGFR mutation in advanced non-small-cell lung cancer that has spread. Both drugs are designed to block cancer growth signals. The study aims to see which one works better as a first treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.